Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib

Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Gil, Alfonso, Escamilla-Gómez, Virginia, Nufer, Melanie, Andújar-Sánchez, Félix, Lopes-Ramos, Teresa, Bejarano-García, José Antonio, García-Guerrero, Estefanía, Calderón-Cabrera, Cristina, Caballero-Velázquez, Teresa, García-Calderón, Clara Beatriz, Hernández-Díaz, Paola, Reguera-Ortega, Juan Luis, Rodríguez-Torres, Nancy, Martínez-Cibrián, Nuria, Rodríguez-Barbosa, José Ignacio, Villadiego, Javier, Pérez-Simón, José Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120462/
https://www.ncbi.nlm.nih.gov/pubmed/35589917
http://dx.doi.org/10.1038/s41598-022-12407-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120462/
https://www.ncbi.nlm.nih.gov/pubmed/35589917
http://dx.doi.org/10.1038/s41598-022-12407-x

Ejemplares similares